

Rafael de la Camara

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6314499/rafael-de-la-camara-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

5,468
citations

39
h-index

70
g-index

193
ext. papers

6,690
ext. citations

5.1
avg, IF

5.03
L-index

#	Paper	IF	Citations
169	Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. <i>Bone Marrow Transplantation</i> , 2009 , 43, 757-70	4.4	259
168	Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. <i>Bone Marrow Transplantation</i> , 2008 , 42, 227-40	4.4	223
167	Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 479-84	4.4	221
166	Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. <i>Haematologica</i> , 2016 , 101, 803-11	6.6	181
165	Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. <i>British Journal of Haematology</i> , 2002 , 116, 475-82	4.5	175
164	Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2005 , 35, 737-46	4.4	171
163	Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 734-48	4.7	166
162	Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. <i>American Journal of Transplantation</i> , 2007 , 7, 2579-86	8.7	159
161	Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 2012 , 55, 794-800	11.6	150
160	Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. <i>Clinical Infectious Diseases</i> , 2014 , 59, 473-81	11.6	149
159	Randomized study of valgacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. <i>Blood</i> , 2002 , 99, 3050-6	2.2	145
158	Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). <i>Lancet Infectious Diseases</i> , 2019 , 19, e260-e272	25.5	137
157	Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1819-1828	11.6	116
156	Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. <i>Haematologica</i> , 2010 , 95, 1762-8	6.6	107
155	Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. <i>Haematologica</i> , 2011 , 96, 1231-5	6.6	103
154	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2071-2076	4.4	102
153	Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1392-401	11.6	90

152	Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. <i>Clinical Infectious Diseases</i> , 2004 , 38, 335-41	11.6	85
151	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020 , 55, 126-136	4.4	82
150	Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2004 , 33, 1075-81	4.4	81
149	Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. <i>Annals of Hematology</i> , 2003 , 82, 80-82	3	76
148	Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 26, 291-8	4.4	76
147	IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 72-80.e8	11.5	74
146	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018 , 76, 20-37	18.9	73
145	European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. <i>Transplant Infectious Disease</i> , 2013 , 15, 219-32	2.7	73
144	A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation. <i>Clinical Microbiology and Infection</i> , 2015 , 21, e1-3	9.5	71
143	CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. <i>Blood</i> , 2007 , 110, 461-7	2.2	69
142	Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 1998 , 21, 473-6	4.4	62
141	Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 341-7	4.4	62
140	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation. <i>British Journal of Haematology</i> , 2001 , 114, 931-6	4.5	60
139	Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. <i>Bone Marrow Transplantation</i> , 1997 , 19, 129-33	4.4	59
138	Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. <i>Vaccine</i> , 2010 , 28, 2730-4	4.1	57
137	Reconstitution of CMV pp65 and IE-1-specific IFN- γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011 , 46, 1437-43	4.4	54
136	Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFN γ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2010 , 45, 543-9	4.4	49
135	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011 , 96, 1470-7	6.6	48

134	Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. <i>Clinical Transplantation</i> , 2011 , 25, E629-38	3.8	47
133	Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation. <i>Haematologica</i> , 2000 , 85, 1060-7	6.6	46
132	Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. <i>Haematologica</i> , 2019 , 104, 2155-2163	6.6	44
131	Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. <i>Bone Marrow Transplantation</i> , 2006 , 37, 33-40	4.4	40
130	Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. <i>Haematologica</i> , 2008 , 93, 1434-6	6.6	39
129	CMV in Hematopoietic Stem Cell Transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016031	3.2	39
128	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1651-1664	4.4	36
127	Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. <i>Bone Marrow Transplantation</i> , 2002 , 30, 963-6	4.4	35
126	Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. <i>Bone Marrow Transplantation</i> , 1992 , 10, 541-6	4.4	35
125	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. <i>Bone Marrow Transplantation</i> , 2020 , 55, 641-648	4.4	35
124	Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. <i>Haematologica</i> , 2003 , 88, 762-8	6.6	35
123	Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. <i>Haematologica</i> , 2009 , 94, 1282-8	6.6	34
122	Treatment and timing in invasive mould disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66 Suppl 1, i37-43	5.1	34
121	High dose busulfan and seizures. <i>Bone Marrow Transplantation</i> , 1991 , 7, 363-4	4.4	33
120	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. <i>Leukemia</i> , 2021 , 35, 2885-2894	10.7	31
119	An assessment of the effect of human herpesvirus-6 replication on active cytomegalovirus infection after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 653-61	4.7	30
118	Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. <i>Haematologica</i> , 2001 , 86, 1075-86	6.6	30
117	Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw107	1	28

116	Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 957-66	4.7	28
115	Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFN γ CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. <i>Journal of Medical Virology</i> , 2010 , 82, 1208-15	19.7	28
114	Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 23, 483-8	4.4	28
113	Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 1995 , 91, 380-6	4.5	28
112	Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2010 , 45, 925-32	4.4	24
111	Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. <i>Bone Marrow Transplantation</i> , 1998 , 22, 47-51	4.4	24
110	Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2012 , 84, 259-67	19.7	23
109	High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha. <i>American Journal of Hematology</i> , 2003 , 72, 170-6	7.1	23
108	Penicillium brevicompactum as the cause of a necrotic lung ball in an allogeneic bone marrow transplant recipient. <i>Bone Marrow Transplantation</i> , 1996 , 18, 1189-93	4.4	23
107	Hla-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease. <i>Transplantation</i> , 2004 , 77, 1107-10	1.8	22
106	Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2015 , 17, 361-70	2.7	21
105	Recurrent disseminated skin lesions due to Metarrhizium anisopliae in an adult patient with acute myelogenous leukemia. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 651-5	9.7	21
104	Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience. <i>Transplantation</i> , 2011 , 92, e17-20	1.8	20
103	Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 664-71	4.7	20
102	Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation. <i>British Journal of Dermatology</i> , 2003 , 148, 1129-34	4	20
101	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. <i>Blood Advances</i> , 2018 , 2, 1719-1737	7.8	20
100	Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. <i>Revista Iberoamericana De Micologia</i> , 2013 , 30, 64-8	1.6	18
99	Minor histocompatibility antigen HA-8 mismatch and clinical outcome after HLA-identical sibling donor allogeneic stem cell transplantation. <i>Haematologica</i> , 2005 , 90, 1723-4	6.6	18

98	Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes. <i>Journal of Medical Virology</i> , 2015 , 87, 248-55	19.7	17
97	Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, 1001-1012	25.5	16
96	Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. <i>Antiviral Therapy</i> , 2011 , 16, 951-7	1.6	16
95	Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. <i>Bone Marrow Transplantation</i> , 1998 , 21, 779-86	4.4	16
94	Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 2741-4	9.7	14
93	Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. <i>Bone Marrow Transplantation</i> , 2015 , 50, 274-81	4.4	14
92	Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication. <i>Bone Marrow Transplantation</i> , 2017 , 52, 832-838	4.4	13
91	Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. <i>BMC Infectious Diseases</i> , 2012 , 12, 83	4	13
90	Defective interleukin 2 receptor expression is associated with the T cell dysfunction subsequent to bone marrow transplantation. <i>European Journal of Immunology</i> , 1987 , 17, 1167-74	6.1	13
89	Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. <i>Haematologica</i> , 1997 , 82, 668-75	6.6	13
88	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021 , 35, 3585-3588	10.7	12
87	UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 79-82	4.4	11
86	Multiple spondylodiscitis caused by <i>Blastoschizomyces capitatus</i> in an allogeneic bone marrow transplantation recipient. <i>Journal of Rheumatology</i> , 1998 , 25, 2276-8	4.1	11
85	Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. <i>Expert Review of Hematology</i> , 2011 , 4, 9-16	2.8	10
84	Erythropoietin in the treatment of delayed immune hemolysis of a major ABO-incompatible bone marrow transplant. <i>American Journal of Hematology</i> , 1994 , 45, 237-9	7.1	10
83	IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2017 , 89, 685-695	19.7	9
82	Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source. <i>Leukemia</i> , 2006 , 20, 1461-4	10.7	9
81	Nephrotic syndrome in a bone marrow transplant recipient after cyclosporine withdrawal. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 2457	4.3	9

80	Can COVID-19 cause severe neutropenia?. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 3349-3351	0.7	8
79	The Genotype of the Donor for the (GT) _n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2015 , 10, e0140454	3.7	8
78	Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection. <i>Bone Marrow Transplantation</i> , 2011 , 46, 1484-6	4.4	8
77	Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. <i>Bone Marrow Transplantation</i> , 1994 , 13, 383-7	4.4	8
76	Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2021 , 11, 13134	4.9	8
75	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1171-1174	4.4	8
74	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	8
73	Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. <i>Advances in Therapy</i> , 2017 , 34, 2104-2119	4.1	7
72	Allogeneic bone marrow transplantation for high risk acute lymphoblastic leukemia. Results from a single institution. <i>Bone Marrow Transplantation</i> , 1992 , 9, 433-8	4.4	7
71	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1493-1508	4.4	7
70	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1564-1575	7	7
69	Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older. <i>Haematologica</i> , 2002 , 87, 965-72	6.6	7
68	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	7
67	Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 512-6	4.7	6
66	Update on viral infections in immunocompromised patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007 , 25, 2-11	0.9	6
65	Recommendations for vaccination against pneumococcus in kidney patients in Spain. <i>Nefrología</i> , 2014 , 34, 545-51	1.5	6
64	Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Health Economics</i> , 2018 , 19, 627-636	3.6	5
63	PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation. <i>Annals of Hematology</i> , 2018 , 97, 2217-2224	3	5

62	An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation. <i>Journal of Medical Virology</i> , 2014 , 86, 806-11	19.7	5
61	A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1205-11	4.4	5
60	A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2013 , 88, 883-9	7.1	5
59	Increased incidence of CMV infection after allogeneic bone marrow transplantation from unrelated donors but doubts about an increase in CMV-associated disease. <i>Bone Marrow Transplantation</i> , 1997 , 20, 181	4.4	5
58	Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia. <i>Journal of Medical Virology</i> , 2015 , 87, 1601-7	19.7	4
57	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2060-2071	4.4	4
56	Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 2042-2047	4.7	4
55	The direct antiglobulin test is frequently positive in chronic myeloid leukemia patients treated with interferon-alpha. <i>Transfusion</i> , 1997 , 37, 446-7	2.9	4
54	Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality. <i>Journal of Infection</i> , 2020 , 81, 882-894	18.9	4
53	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. <i>American Journal of Transplantation</i> , 2021 , 21, 258-271	8.7	4
52	Bronchoalveolar lavage cell composition in allogeneic bone marrow transplant patients without symptomatic lung complications. <i>Bone Marrow Transplantation</i> , 1997 , 20, 1087-93	4.4	3
51	COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). <i>Blood</i> , 2020 , 136, 22-23	2.2	3
50	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2021 , 1-13	1.9	3
49	Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2021 , 100, 763-777	3	3
48	Lactic Acidosis in Non-Hodgkin's Lymphoma and response to Chemotherapy. <i>Haematologica</i> , 2002 , 87, ELT05	6.6	3
47	Cutaneous lesions as the first sign of disseminated mucormycosis. <i>Acta Dermato-Venereologica</i> , 1995 , 75, 166-7	2.2	3
46	Non conjugate pneumococcal vaccine and Haemophilus influenzae type b vaccine in haemopoietic transplantation. <i>Vacunas</i> , 2003 , 4, 30-33	0.9	2
45	Voriconazole for Secondary Prophylaxis of Invasive Fungal Infection in Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study. on Behalf of the VOSIFI Study Group and the Infectious Diseases Working Party of the European Bone and Marrow Transplantation Group.. <i>Blood</i> , 2008 , 112, 1158-1159	2.2	2

44	Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	2
43	Vaccinations 2019 , 207-219		2
42	Study of cytomegalovirus resistance in allogeneic hematopoietic cell transplant recipients. <i>Medicina Clínica</i> , 2020 , 154, 433-439	1	2
41	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1281-1290	4.4	2
40	Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT. <i>Bone Marrow Transplantation</i> , 2015 , 50, 298-300	4.4	1
39	Effect of cytomegalovirus (CMV) serostatus on the incidence and virological features of active CMV infection in allogeneic stem cell transplant recipients. <i>Clinical Infectious Diseases</i> , 2011 , 53, 313-5; author reply 315-6	11.6	1
38	Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. <i>Leukemia</i> , 2004 , 18, 1031-4	10.7	1
37	Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. <i>Leukemia</i> , 2004 , 18, 1165-7	10.7	1
36	Does high-dose prophylactic acyclovir add benefit in allogeneic marrow transplant recipients receiving prophylactic or preemptive ganciclovir?. <i>Journal of Infectious Diseases</i> , 1999 , 180, 571-4	7	1
35	Unexpectedly high toxicity of MACOP-B in young patients with low grade lymphoma. <i>American Journal of Hematology</i> , 1991 , 38, 75-6	7.1	1
34	Immune Response to the 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23) after the 7-Valent Conjugate Vaccine (PCV7) in Allogeneic Stem Cell Transplant (SCT) Recipients: Results of the EBMT IDWP01 Trial. <i>Blood</i> , 2008 , 112, 350-350	2.2	1
33	Prospective Study of Oral Valganciclovir for Pre-Emptive Therapy of Cytomegalovirus After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2009 , 114, 1168-1168	2.2	1
32	Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). <i>Blood</i> , 2014 , 124, 666-666	2.2	1
31	Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. <i>BMJ Open</i> , 2020 , 10, e037443	3	1
30	HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	1
29	Study of cytomegalovirus resistance in allogeneic hematopoietic cell transplant recipients. <i>Medicina Clínica (English Edition)</i> , 2020 , 154, 433-439	0.3	1
28	Nocardia infections in hematopoietic cell transplant recipients: a multicenter international retrospective study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
27	Update on fungemia in oncology and hematology. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011 , 29 Suppl 4, 42-7	0.9	0

26	Antifungal prophylaxis in haematology patients. <i>Clinical Microbiology and Infection</i> , 2006 , 12, 65-76	9.5	o
25	COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). <i>Blood</i> , 2021 , 138, 2866-2866	2.2	o
24	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. <i>Transplant Infectious Disease</i> , 2021 , 23, e13627	2.7	o
23	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1563-1572	4.4	o
22	Multiple pretibial cutaneous relapses of acute myeloblastic leukemia after allogeneic BMT. <i>Bone Marrow Transplantation</i> , 2009 , 43, 819-20	4.4	
21	Inadequate references in recent article. <i>American Journal of Health-System Pharmacy</i> , 2012 , 69, 917-22; author reply 922	2.2	
20	Update on pulmonary infections in patients with hematologic malignancies and hematopoietic stem cell recipients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2008 , 26, 58-71	0.9	
19	Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups. <i>Blood</i> , 2020 , 136, 19-19	2.2	
18	Discrepancies in the management of Clostridioides difficile infections in patients after allogeneic haematopoietic cell transplantation: the results of the Infectious Diseases Working Party EBMT survey.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	
17	Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Blood</i> , 2021 , 138, 2818-2818	2.2	
16	Reduced Intensity Conditioning Unrelated Transplant Plus Cyclosporine and MMF as GVHD Prophylaxis: Results of a Prospective Study.. <i>Blood</i> , 2005 , 106, 5312-5312	2.2	
15	COVID-19-induced thrombocytopenia. <i>Acta Haematologica Polonica</i> , 2020 , 51, 261-262	0.4	
14	CCR7 As a New Biomarker in Graft-Versus-Host Disease: T Cells Expressing the Homing Receptor CCR7 Mediate the Pathogenesis of Gvhd. <i>Blood</i> , 2014 , 124, 3930-3930	2.2	
13	The Role of CMV Serostatus of the Donor in the Graft Lymphoid Composition and Prediction of Gvhd and CMV Reactivation. <i>Blood</i> , 2014 , 124, 2422-2422	2.2	
12	A New Multiple Single-Nucleotide Polymorphisms Based Predictive Model for Grades III to IV and Extensive Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell. <i>Blood</i> , 2015 , 126, 921-921	2.2	
11	Allogeneic Hematopoietic Stem Cell Transplant in Advanced Multiple Myeloma: Experience from a Single Center. <i>Blood</i> , 2015 , 126, 5536-5536	2.2	
10	Assessment of the Impact of Human Herpesvirus 6 (HHV-6) Replication On Active Citomegalovirus (CMV) Infection After Allogeneic Stem Cell Transplantation (Allo-SCT).. <i>Blood</i> , 2009 , 114, 2225-2225	2.2	
9	The Genotype of the Donor for the Polymorphism A7488G of the IL-17 Gene Influences relapse and survival After HLA-Identical Related Stem Cell Transplantation.. <i>Blood</i> , 2010 , 116, 1302-1302	2.2	

- 8 Myeloablative Conditioning with Intravenous Busulfan In One Daily Dose and Fludarabine (BUF) for HLA-Identical Sibling Allogeneic HSCT In Myeloid Malignancies. *Blood*, **2011**, 118, 3010-3010 2.2
- 7 The Combination of Siromilus Plus Tacrolimus (SiTac) Improves the Results of Cyclosporine Plus Mycophenolate Mofetil (CsAMMF) After Reduced Intensity Conditioning (RIC) Unrelated Donor Allogeneic Transplantation. *Blood*, **2011**, 118, 890-890 2.2
- 6 A Recessive Gene Variant in TGFB1 in the Donor Influences the Acute Graft Versus Host Disease Development and Impacts in the Outcome After Allogeneic Stem Cell Transplantation (Allo-SCT),. *Blood*, **2011**, 118, 4080-4080 2.2
- 5 -52G/A Gene Variant in the Defensin-1 (DEBF1) Influences the Development of Severe Acute Graft Versus Host Disease (aGvHD) After Allogeneic Stem Cell Transplantation (Allo-SCT). Functional Association of This Variant with a Low Anti- Inflammatory Response. *Blood*, **2011**, 118, 3052-3052 2.2
- 4 G to C Transition At Position 173 of MIF Gene Associates with Poor Survival in Acute Myeloid Leukemia Patients and After Allogeneic Stem Cell Transplantation (Allo-SCT). *Blood*, **2011**, 118, 2530-2530 2.2
- 3 A Gene Variant in IRF3 Impacts On the Clinical Outcome of Acute Myeloid Leukemia (AML) Patients Submitted to Allogeneic Stem Cell Transplantation (allo-SCT). *Blood*, **2012**, 120, 468-468 2.2
- 2 Donor CMV Status Influence On the Outcome of Allogeneic Stem Cell Transplantation (HSCT); A Study by the Infectious Diseases Working Party (IDWP) of the EBMT. *Blood*, **2012**, 120, 465-465 2.2
- 1 Donor Genotypes For Interleukin-17A Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation Of Complications After HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). *Blood*, **2013**, 122, 4619-4619 2.2